Significant dose Escalation of Idarubicin in the treatment of aggressive Non- Hodgkin Lymphoma leads to increased hematotoxicity without improvement in efficacy in comparison to standard CHOEP-14: 9-year follow up results of the CIVEP trial of the DSHNHL

@article{Hohloch2014SignificantDE,
  title={Significant dose Escalation of Idarubicin in the treatment of aggressive Non- Hodgkin Lymphoma leads to increased hematotoxicity without improvement in efficacy in comparison to standard CHOEP-14: 9-year follow up results of the CIVEP trial of the DSHNHL},
  author={K. Hohloch and C. Zwick and M. Ziepert and D. Hasenclever and U. Kaiser and A. Engert and H. Hoeffkes and F. Kroschinsky and R. Mesters and Andreas Feller and M. Loeffler and L. Tr{\"u}mper and M. Pfreundschuh},
  journal={SpringerPlus},
  year={2014},
  volume={3}
}
  • K. Hohloch, C. Zwick, +10 authors M. Pfreundschuh
  • Published 2014
  • Medicine
  • SpringerPlus
  • BackgroundDose escalation and modification of CHOP has improved the prognosis of patients with aggressive lymphoma; even in the rituximab era, dose escalation for high-risk patients is exploited and frequently limited by drug toxicity. Idarubicin (Id) is a 4-demethoxy anthracycline analogue of daunorubicin with activity against lymphoma and has been reported to cause less cardiotoxicity than other anthracylines. The aim of this study was to replace doxorubicine with idarubicin in the CHOEP… CONTINUE READING
    7 Citations

    References

    SHOWING 1-10 OF 30 REFERENCES
    Comparison of CHOP versus CIOP in good prognosis younger patients with histologically aggressive non‐Hodgkin lymphoma
    • 19
    Increased myelotoxicity of idarubicin: is there a pharmacological basis?
    • 3
    Phase III comparative trial using CHOP vs CIOP in the treatment of advanced intermediate-grade non-Hodgkin's lymphoma.
    • 32
    • Highly Influential
    EPOCH chemotherapy: toxicity and efficacy in relapsed and refractory non-Hodgkin's lymphoma.
    • W. Wilson, G. Bryant, +7 authors B. Cheson
    • Medicine
    • Journal of clinical oncology : official journal of the American Society of Clinical Oncology
    • 1993
    • 236
    Long-term results of the R-CHOP study in the treatment of elderly patients with diffuse large B-cell lymphoma: a study by the Groupe d'Etude des Lymphomes de l'Adulte.
    • 1,206
    • PDF